Immediate Impact
67 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
Works of Astrid Jullion being referenced
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
2021
Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Astrid Jullion | 79 | 52 | 47 | 70 | 14 | 228 | |
| Robert W. Corty | 68 | 26 | 35 | 48 | 17 | 245 | |
| Sven Stodtmann | 40 | 11 | 15 | 54 | 25 | 236 | |
| Zorayr Manukyan | 49 | 13 | 27 | 49 | 16 | 280 | |
| Grace Hsu | 47 | 64 | 67 | 74 | 13 | 256 | |
| Tuochuan Dong | 132 | 24 | 21 | 44 | 9 | 284 | |
| Anders Ellern Bilgrau | 76 | 16 | 13 | 45 | 20 | 255 | |
| Lingmin Zeng | 34 | 36 | 98 | 67 | 18 | 196 | |
| Susan Jin | 28 | 18 | 27 | 71 | 11 | 252 | |
| Andrew J. Sedgewick | 158 | 10 | 22 | 47 | 14 | 279 | |
| Małgorzata Krętowska | 49 | 7 | 53 | 26 | 22 | 288 |
All Works
Loading papers...